| Item Type | Name |
|
Concept
|
Albuminuria
|
|
Academic Article
|
Angiotensin-converting enzyme inhibitors and progression of diabetic nephropathy.
|
|
Academic Article
|
Comparative effects of different antihypertensive treatments on progression of diabetic renal disease.
|
|
Academic Article
|
Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists.
|
|
Academic Article
|
Effects of dihydropyridine calcium antagonists on albuminuria in patients with diabetes.
|
|
Academic Article
|
Predictors of renal and cardiovascular mortality in patients with non-insulin-dependent diabetes: a brief overview of microalbuminuria and insulin resistance.
|
|
Academic Article
|
Microalbuminuria: what is it? Why is it important? What should be done about it?
|
|
Academic Article
|
Risks for renal involvement in diabetes.
|
|
Academic Article
|
Renal handling of albumin: a critical review of basic concepts and perspective.
|
|
Academic Article
|
Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study.
|
|
Academic Article
|
Microalbuminuria in diabetes: focus on cardiovascular and renal risk reduction.
|
|
Academic Article
|
Rosiglitazone reduces urinary albumin excretion in type II diabetes.
|
|
Academic Article
|
How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy?
|
|
Academic Article
|
Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK).
|
|
Academic Article
|
ImmunoDip: an improved screening method for microalbuminuria.
|
|
Academic Article
|
Blood pressure control and nephroprotection in diabetes.
|
|
Academic Article
|
Inclusion of albuminuria in hypertension and heart guidelines.
|
|
Academic Article
|
Comparison of commonly used assays for the detection of microalbuminuria.
|
|
Academic Article
|
Protecting renal function in the hypertensive patient: clinical guidelines.
|
|
Academic Article
|
Implications of albuminuria on kidney disease progression.
|
|
Academic Article
|
Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes.
|
|
Academic Article
|
Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria.
|
|
Academic Article
|
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial.
|
|
Academic Article
|
Obesity and insulin resistance as risk factors for chronic kidney disease.
|
|
Academic Article
|
Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes.
|
|
Academic Article
|
Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease.
|
|
Academic Article
|
Clinical importance of microalbuminuria in diabetes and hypertension.
|
|
Academic Article
|
A comparative evaluation of various methods for microalbuminuria screening.
|
|
Academic Article
|
Race and sex differences in hypertension control in CKD: results from the Kidney Early Evaluation Program (KEEP).
|
|
Academic Article
|
Slowing the progression of diabetic nephropathy and its cardiovascular consequences.
|
|
Academic Article
|
Should a lower blood pressure goal and albuminuria reduction be mandated to slow hypertensive nephropathy?
|
|
Academic Article
|
Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
|
|
Academic Article
|
The current state of RAAS blockade in the treatment of hypertension and proteinuria.
|
|
Academic Article
|
The effect of ruboxistaurin on nephropathy in type 2 diabetes.
|
|
Academic Article
|
Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians.
|
|
Academic Article
|
Protection of the kidney by thiazolidinediones: an assessment from bench to bedside.
|
|
Academic Article
|
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
|
|
Academic Article
|
Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?
|
|
Academic Article
|
Microalbuminuria: what is it? Why is it important? What should be done about it? An update.
|
|
Academic Article
|
Albuminuria and cardiovascular risk.
|
|
Academic Article
|
Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP).
|
|
Academic Article
|
Importance of blood pressure control in left ventricular mass regression.
|
|
Academic Article
|
Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy.
|
|
Academic Article
|
The pathogenesis of diabetic nephropathy.
|
|
Academic Article
|
Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP).
|
|
Academic Article
|
Prehypertension: is it relevant for nephrologists?
|
|
Academic Article
|
Influence of microalbuminuria in achieving blood pressure goals.
|
|
Academic Article
|
Antihypertensive therapy and progression of diabetic renal disease.
|
|
Academic Article
|
Serum creatinine vs. albuminuria as biomarkers for the estimation of cardiovascular risk.
|
|
Academic Article
|
Prevention of microalbuminuria in patients with type 2 diabetes: what do we know?
|
|
Academic Article
|
Telmisartan in incipient and overt diabetic renal disease.
|
|
Academic Article
|
Microalbuminuria and progressive renal disease.
|
|
Academic Article
|
ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects.
|
|
Academic Article
|
Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study.
|
|
Academic Article
|
Microalbuminuria in non-insulin-dependent diabetes mellitus. Implications for renal survival.
|
|
Academic Article
|
Effects of angiotensin II receptor blockers on diabetic nephropathy.
|
|
Academic Article
|
Intensive blood-pressure control in hypertensive chronic kidney disease.
|
|
Academic Article
|
Renal function and target organ damage in hypertension.
|
|
Academic Article
|
Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus.
|
|
Academic Article
|
Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus.
|
|
Academic Article
|
A reappraisal of renin-angiotensin system blockade on microalbuminuria development: do they offer anything unique?
|
|
Academic Article
|
Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the Kidney Early Evaluation Program (KEEP).
|
|
Academic Article
|
When to refer patients to a nephrologist?
|
|
Academic Article
|
Albuminuria reduction and nephropathy progression.
|
|
Academic Article
|
Pathogenesis and treatment of microalbuminuria in patients with diabetes: the road ahead.
|
|
Academic Article
|
Hypertensive nephropathy: prevention and treatment recommendations.
|
|
Academic Article
|
Gestational diabetes mellitus alone in the absence of subsequent diabetes is associated with microalbuminuria: results from the Kidney Early Evaluation Program (KEEP).
|
|
Academic Article
|
Microalbuminuria as a risk predictor in diabetes: the continuing saga.
|
|
Academic Article
|
Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease.
|
|
Academic Article
|
Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy.
|
|
Academic Article
|
Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the ONTARGET and TRANSCEND studies.
|
|
Academic Article
|
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
|
|
Academic Article
|
Finerenone for Albuminuria in Patients With Diabetic Nephropathy--Reply.
|
|
Academic Article
|
Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?
|
|
Academic Article
|
Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
|
|
Academic Article
|
Mineralocorticoid antagonists in chronic kidney disease.
|
|
Academic Article
|
Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease.
|
|
Academic Article
|
Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.
|
|
Academic Article
|
MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol.
|
|
Academic Article
|
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
|
|
Academic Article
|
Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL.
|
|
Academic Article
|
Non-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease.
|
|
Academic Article
|
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
|
|
Academic Article
|
Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial.
|
|
Academic Article
|
Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes?
|
|
Academic Article
|
Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial.
|
|
Academic Article
|
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
|
|
Academic Article
|
Effects of the Soluble Guanylate Cyclase Stimulator Praliciguat in Diabetic Kidney Disease: A Randomized Placebo-Controlled Clinical Trial.
|
|
Academic Article
|
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.
|
|
Academic Article
|
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
|
|
Academic Article
|
Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial.
|
|
Academic Article
|
Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.
|
|
Academic Article
|
The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Randomized Trial.
|
|
Academic Article
|
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER.
|
|
Academic Article
|
Kidney function assessment and endpoint ascertainment in clinical trials.
|
|
Academic Article
|
Generalizability of FIGARO-DKD and FIDELIO-DKD Trial Criteria to the US Population Eligible for Finerenone.
|
|
Academic Article
|
Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study.
|
|
Academic Article
|
A Non-purine Xanthine Oxidoreductase Inhibitor Reduces Albuminuria in Patients with DKD: A Randomized Controlled Trial.
|
|
Academic Article
|
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.
|
|
Academic Article
|
Finerenone and Heart Failure Outcomes by Kidney Function/Albuminuria in Chronic Kidney Disease and Diabetes.
|
|
Academic Article
|
Blood Pressure and Cardiorenal Outcomes With Finerenone in Chronic Kidney Disease in Type 2 Diabetes.
|
|
Academic Article
|
Albuminuria and Heart Failure: JACC State-of-the-Art Review.
|
|
Academic Article
|
Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.
|
|
Academic Article
|
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
|
|
Academic Article
|
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis.
|
|
Academic Article
|
Albuminuria is Your Guide to Assessing Future GFR Slope.
|